BRPI0615135A2 - composições de fármacos contendo matrizes de hipromelose de liberação controlada - Google Patents

composições de fármacos contendo matrizes de hipromelose de liberação controlada

Info

Publication number
BRPI0615135A2
BRPI0615135A2 BRPI0615135A BRPI0615135A BRPI0615135A2 BR PI0615135 A2 BRPI0615135 A2 BR PI0615135A2 BR PI0615135 A BRPI0615135 A BR PI0615135A BR PI0615135 A BRPI0615135 A BR PI0615135A BR PI0615135 A2 BRPI0615135 A2 BR PI0615135A2
Authority
BR
Brazil
Prior art keywords
controlled release
compositions containing
drug compositions
containing controlled
matrices
Prior art date
Application number
BRPI0615135A
Other languages
English (en)
Inventor
Ali Rajabi-Siahboomi
Aln Kurt Fegely
Kara Young
Pankaj Rege
Original Assignee
Bpsi Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bpsi Holdings Inc filed Critical Bpsi Holdings Inc
Publication of BRPI0615135A2 publication Critical patent/BRPI0615135A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0615135A 2005-08-26 2006-08-25 composições de fármacos contendo matrizes de hipromelose de liberação controlada BRPI0615135A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71172405P 2005-08-26 2005-08-26
PCT/US2006/033309 WO2007025182A2 (en) 2005-08-26 2006-08-25 Drug compositions containing controlled release hypromellose matrices

Publications (1)

Publication Number Publication Date
BRPI0615135A2 true BRPI0615135A2 (pt) 2016-09-13

Family

ID=37772457

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615135A BRPI0615135A2 (pt) 2005-08-26 2006-08-25 composições de fármacos contendo matrizes de hipromelose de liberação controlada

Country Status (13)

Country Link
US (1) US20070048377A1 (pt)
EP (1) EP1926479A4 (pt)
JP (1) JP2009506070A (pt)
KR (1) KR20080047571A (pt)
CN (1) CN101247790A (pt)
AU (1) AU2006282900B2 (pt)
BR (1) BRPI0615135A2 (pt)
CA (1) CA2620108A1 (pt)
IL (1) IL189631A0 (pt)
MX (1) MX2008002512A (pt)
RU (1) RU2414241C2 (pt)
WO (1) WO2007025182A2 (pt)
ZA (1) ZA200801478B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068076A2 (en) * 2010-11-15 2012-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations containing soluble drugs
NL2009273A (en) 2011-08-31 2013-03-04 Asml Netherlands Bv Level sensor arrangement for lithographic apparatus, lithographic apparatus and device manufacturing method.
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
RU2624857C1 (ru) * 2016-01-26 2017-07-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Фармацевтическая композиция с противогрибковой активностью и способ ее получения
EP3711763A4 (en) 2017-11-16 2021-08-18 Nippon Shinyaku Co., Ltd. CONTROLLED RELEASE FORMULATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
JP2006507298A (ja) * 2002-10-30 2006-03-02 ファルマシア コーポレーション 経口持続放出型錠剤、ならびにその製造法および使用法
ES2545454T3 (es) * 2002-12-10 2015-09-11 Nortec Development Associates, Inc. Método de preparación de formulaciones biológicamente activas
US7314638B2 (en) * 2003-08-12 2008-01-01 Kyungdong Pharm. Co., Ltd. Preparing method for controlled released type tablet tamsulosin HCL and the tablet thereof
WO2005034954A2 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
PE20050484A1 (es) * 2003-10-29 2005-10-13 Wyeth Corp Composicion farmaceutica de liberacion sostenida

Also Published As

Publication number Publication date
WO2007025182A2 (en) 2007-03-01
ZA200801478B (en) 2008-12-31
EP1926479A2 (en) 2008-06-04
EP1926479A4 (en) 2013-01-09
JP2009506070A (ja) 2009-02-12
US20070048377A1 (en) 2007-03-01
CN101247790A (zh) 2008-08-20
MX2008002512A (es) 2008-04-03
IL189631A0 (en) 2008-06-05
KR20080047571A (ko) 2008-05-29
AU2006282900A1 (en) 2007-03-01
WO2007025182A3 (en) 2007-09-07
CA2620108A1 (en) 2007-03-01
RU2008111497A (ru) 2009-10-10
RU2414241C2 (ru) 2011-03-20
AU2006282900B2 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
BRPI0615135A2 (pt) composições de fármacos contendo matrizes de hipromelose de liberação controlada
IL188964A0 (en) Sustained drug release composition
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ZA200705530B (en) Sustained release pharmaceutical formulations
RU2398586C3 (ru) Фармацевтическая композиция
NO20075628L (no) Farmasøytiske formuleringer
ZA200802602B (en) Controlled release formulation
HK1180949A1 (en) Long lasting drug formulations
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
ZA200708705B (en) Pharmaceutical composition
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
IL184558A0 (en) Sustained release composition of protein drug
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
PL1909761T3 (pl) Kompozycja farmaceutyczna zawierająca granulowany pantoprazol
ZA200706807B (en) Composition containing chitosan for sustained drug release
BRPI0906346A2 (pt) "composição farmacêutica de liberação prolongada"
ZA200606408B (en) Controlled release pharmaceutical compositions
AU2005900624A0 (en) Modified release pharmaceutical composition
BRPI0815893A2 (pt) formulação farmacêutica de liberação prolongada.
ITRE20060121A1 (it) Composizione insetticida solida
GB0518166D0 (en) Pharmaceutical composition
GB0511801D0 (en) Pharmaceutical composition
ZA200800392B (en) Pharmaceutical composition

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20080027557/RJ DE 25/02/2008.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.